A novel approach to assess real-world efficacy of cancer therapy in metastatic prostate cancer. Analysis of national data on Veterans treated with abiraterone and enzalutamide

Harshraj Leuva,Keith Sigel,Mengxi Zhou,Julia Wilkerson,David H. Aggen,Yeun-Hee Anna Park,Christopher B. Anderson, Ta-Chueh Melody Hsu,Erik Langhoff, Glen McWilliams,Charles G. Drake,Richard Simon,Susan E. Bates,Tito Fojo

Seminars in Oncology（2019）

引用 14|浏览40

暂无评分

摘要

Background: With 1.3 million new cases in 2018 worldwide, prostate cancer remains a challenge. Development of novel therapies targeting the androgen pathway followed recognition of the continued importance of androgens in castrate-resistant prostate cancer. To assess abiraterone and enzalutamide efficacy we analyzed data from US Veterans Administration Medical Centers (VAMCs).

查看译文

关键词

Prostate cancer,Real-world data,Veterans Administration,VINCI,African Americans,Abiraterone,Enzalutamide,Health care disparities,Data warehouses,CRPC,Growth rate

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要